Pulmonary nocardiosis following pembrolizumab use: case report and literature review of nocardiosis associated with immune checkpoint inhibitors.

Authors

Takashi Koyama, Kei Furui Ebisawa, Tatsuki Mizobe, Goh Ohji, Tsugumi Kaku, Shun Yamazaki, Daisuke Hazama, Kentaro Iwata

Published in

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. Pages 103065. Sep 04, 2026. Epub Sep 04, 2026.

Abstract

A woman in her 80s, who had a history of treatment with pembrolizumab for biliary tract cancer and was taking low-dose corticosteroids for immune-related adverse events (irAEs) involving nephritis and hepatitis, was admitted to the hospital complaining of a cough and increased sputum production that had begun two weeks prior. Computed tomography (CT) revealed patchy infiltrates predominantly in the lower lobes of both lungs. Since one of the Nocardia species was detected in the sputum collected at admission, we diagnosed her with pulmonary nocardiosis. In addition to this case, other cases of nocardiosis that developed following the use of immune checkpoint inhibitors (ICIs) have been reported. These cases include instances in which nocardiosis developed despite the absence of immunosuppressive therapy. Here, we review nocardiosis following ICI use.

PMID:
42697330
Bibliographic data and abstract were imported from PubMed on 05 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.